Hanmi Pharmaceutical's third quarter operating profit was 37.8 billion won... Cumulative sales: KRW 1.2 trillion (comprehensive)

(Seoul = Yonhap News) Reporter Park Sang-hyun = Hanmi Pharmaceutical [128940] announced on the 27th that its consolidated operating profit in the third quarter of this year was provisionally calculated to be 37.8 billion won, a 31.3% decrease from the same period last year.

Sales amounted to 377.4 billion won, an increase of 4.2% compared to the same period last year. Net profit decreased by 69.1% to 14 billion won.

Hanmi Pharmaceutical's annual cumulative operating profit was 222.5 billion won and sales were 1.2376 trillion won.

Hanmi Pharmaceutical analyzed that operating profit decreased in the third quarter, but sales increased due to the solid growth of major products such as 'Rosujet', a dyslipidemia treatment drug.

The company reported that this year's cumulative outpatient prescription sales amounted to 783.5 billion won, making it likely to rank first for the 9th consecutive year.

Rosuzet's outpatient prescription sales in the third quarter recorded KRW 65.2 billion, a 10.6% increase from the previous year.

Hanmi Pharmaceutical said, “We are continuously nurturing next-generation growth products,” and added, “Based on our domestic sales and marketing capabilities and field expertise, we will expand the synergy between existing and new products through close collaboration with medical staff and partnerships with global pharmaceutical companies.”

Beijing Hanmi Pharmaceutical, a local subsidiary in China, recorded sales of 79.3 billion won in the third quarter.

Hanmi Pharmaceutical explained that it is suspending new transactions with respect to the distribution network where concerns have been raised until Beijing Hanmi's trade receivables are collected and has further strengthened its internal control system.

Hanmi Fine Chemical, a raw material pharmaceutical affiliate, had sales of 22.8 billion won in the third quarter.

Hanmi Pharmaceutical announced that it plans to build a full-cycle portfolio for obesity, focusing on 'EPE', Korea's first glucagon-like peptide-1 (GLP-1) type obesity treatment drug, which will begin prescriptions on the 29th.